Atopic Dermatitis (Adult Recalcitrant, EASI >21)

Investigational adjunct for adult recalcitrant atopic dermatitis (EASI >21) refractory to dupilumab or JAK inhibitor; very preliminary data.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?: Not FDA-cleared for atopic dermatitis. The FDA cleared medicinal leeches in 2004 (K040187) only for venous congestion in microsurgical reconstruction. Use for atopic dermatitis is investigational.
¿Qué evidencia existe?: Tier C (investigational). A single small case series (n=12) suggests possible improvement; there are no randomized controlled trials. Evidence-based therapy for recalcitrant adult atopic dermatitis is dupilumab, tralokinumab, or oral JAK inhibitors (upadacitinib, abrocitinib), with high-potency topical corticosteroids and calcineurin inhibitors for flares. AAD guidelines recommend stepwise escalation through biologics before considering experimental adjuncts.
Riesgos principales: Bleeding from bite sites for 6 to 24 hours after each leech detaches
Itching, redness, and irritation at bite sites lasting days to weeks
Koebner-like flare of eczema at bite locations in actively inflamed skin
Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
Eczema herpeticum or impetiginization if applied to broken or weeping skin
Allergic reaction to leech saliva (uncommon but possible)
Post-inflammatory hyperpigmentation, especially in darker skin
Delay of evidence-based dupilumab or JAK-inhibitor therapy
Quién no debería considerar esto: Patients with active eczema herpeticum or impetiginized eczema
Patients on JAK inhibitors with severe immunosuppression
Patients with widespread excoriation or secondary bacterial infection
Patients on anticoagulants, with hemophilia, or with severe anemia (Hb <10)
Pregnant or breastfeeding patients
Patients who have not been offered or trialed dupilumab or JAK inhibitors
Qué preguntar a su clínico: Have I been offered dupilumab, tralokinumab, or an oral JAK inhibitor by a dermatologist?
What evidence supports leech therapy specifically for atopic dermatitis like mine?
Will leech application risk triggering a flare or eczema herpeticum at bite sites?
What is the practitioner's Aeromonas-prevention plan and antibiotic protocol?
Are leeches from an FDA-registered supplier and used only once?
How will we know if treatment is working — by EASI score, photographs, or symptoms?
What is the cost and is it covered by insurance? (typically not covered)
Cuándo buscar atención urgente: Rapidly spreading vesicular or punched-out lesions (suspect eczema herpeticum — emergency)
Spreading redness, warmth, pus, or red streaks around bite sites (cellulitis)
Fever above 38.0 C / 100.4 F or chills
Bleeding from a bite site lasting more than 24 hours
Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Severe flare with extensive skin denudation or signs of systemic illness

Qué NO significa esto

This is NOT FDA-cleared for atopic dermatitis — the only FDA clearance (K040187, 2004) is for venous congestion in microsurgical reconstruction.
A single n=12 case series does NOT establish efficacy versus dupilumab or JAK inhibitors.
Leech therapy does NOT substitute for evidence-based topical or systemic therapy.
It does NOT mean leech application is safe on actively weeping, excoriated, or herpetically-infected skin — those settings carry serious risk.
It does NOT mean every patient will improve — individual responses vary and most published cases are uncontrolled.

Referencias cruzadas de seguridad

Clinical Profile

Category: dermatological
ICD-10: L20.0, L20.81, L20.83, L20.84, L20.89
Safety tier: high

Evidence Summary

Recalcitrant adult atopic dermatitis (EASI >21) is conventionally treated with dupilumab, tralokinumab, or oral JAK inhibitors (upadacitinib, abrocitinib). For patients refractory or contraindicated to biologics, options narrow significantly. Direct evidence for leech therapy in this biologic-refractory population is absent. The only clinical study of leech application in eczema is a single open-label trial without a control group (n=27) in general eczema, which reported a 54.45% reduction in EASI score after a minimum of four sittings; it did not enroll EASI >21 biologic-refractory disease. Mechanism is speculative — possibly local Th2 modulation. Evidence is grade D. This entry is distinct from the registry's primary atopic eczema entry, which addresses general moderate disease. Leech application should be placed at the periphery of lichenified plaques, not on excoriated or weeping skin.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Patel J et al. (2022), n=12

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Active eczema herpeticum or impetiginized eczema
Active JAK inhibitor with severe immunosuppression
Widespread excoriation with secondary infection

Related Conditions

Livedo Reticularis

Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.

Lipodermatosclerosis

Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.

Insulin Injection Lipohypertrophy

Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.

Androgenic Alopecia

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.